In the News Archive

In 2010, the need for social services that help underinsured Barnes-Jewish Hospital patients focus on healing instead of worrying about the financial burdens of a hospital stay has increased significantly.

Melanoma is one of a few cancers that have been shown to stimulate a low level immune response toward the tumor in many people. Some gifts donated to the Melanoma Research and Patient Care Fund of the Barnes-Jewish Hospital Foundation are supporting a study to create a melanoma vaccine that increases the immune response and promotes regression of the disease.

He was an accomplished horse trainer, casual pianist, and professional hair designer. But those who were dearest to David Marion would say the best way to describe him is “big brother.”

More than 500 people gathered to raise over $1.6 million at the Barnes-Jewish Hospital Foundation’s “illumination10” gala on Saturday, May 15, 2010 at the Chase Park Plaza. All proceeds will benefit the Cancer Frontier Fund at the Alvin J. Siteman Cancer Center.

Success really does bring more success. For 15 years, David Mutch, MD, a Washington University gynecologic oncologist at Barnes-Jewish Hospital, and Paul Goodfellow*, PhD, a Washington University geneticist, have collaborated on endometrial and ovarian cancer research.

Soon after Mario Schootman, PhD, an epidemiologist, came to Washington University in 1999, he reviewed data from the Missouri Cancer Registry and noticed a disturbing trend among patients with breast cancer:  from 1996 to 1998, women who were 50 and older were twice as likely to have late-stage breast cancer if they lived in certain ZIP codes in the northeastern part of St. Louis.